Litcius/Paper detail

Novel benzimidazole-based pseudo-irreversible butyrylcholinesterase inhibitors with neuroprotective activity in an Alzheimer's disease mouse model

Philipp Spatz, Thomas Zimmermann, Sophie A. M. Steinmüller, Julian Hofmann, Tangui Maurice, Michael Decker

2022RSC Medicinal Chemistry22 citationsDOIOpen Access PDF

Abstract

Benzimidazole-based inhibitors of butyrylcholinesterase were designed and tested for their activity and selectivity in vitro , leading to compound (11d) that attenuated Aβ 25-35 -induced learning impairments in an Alzheimer's disease mouse model.

Topics & Concepts

ButyrylcholinesteraseBenzimidazoleNeuroprotectionCholinesterasePharmacologyAlzheimer's diseaseNeuroscienceDiseaseChemistryMedicineBiochemistryAcetylcholinesteraseBiologyAchéEnzymeInternal medicineOrganic chemistryCholinesterase and Neurodegenerative DiseasesComputational Drug Discovery MethodsNicotinic Acetylcholine Receptors Study
Novel benzimidazole-based pseudo-irreversible butyrylcholinesterase inhibitors with neuroprotective activity in an Alzheimer's disease mouse model | Litcius